The ACUITY trial: a randomized comparison of Angiomax (Bivalirudin) versus heparin (unfractionated heparin or enoxaparin) in patients undergoing early invasive management for acute coronary syndromes without ST-segment elevation

Trial Profile

The ACUITY trial: a randomized comparison of Angiomax (Bivalirudin) versus heparin (unfractionated heparin or enoxaparin) in patients undergoing early invasive management for acute coronary syndromes without ST-segment elevation

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2016

At a glance

  • Drugs Bivalirudin (Primary) ; Abciximab; Enoxaparin sodium; Enoxaparin sodium; Eptifibatide; Heparin; Tirofiban
  • Indications Acute coronary syndromes
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ACUITY
  • Sponsors The Medicines Company
  • Most Recent Events

    • 20 Apr 2016 Results of a pooled analysis from REPLACE-2, ACUITY and HORIZONS-AMI Trials (n=3641) published in the American Journal of Cardiology
    • 01 Dec 2015 Results(n=14,784) of pooled analysis of this and other two trials (see profile 21574 and 266431) published in the American Journal of Cardiology
    • 29 May 2008 The medicines Company received a not approvable letter from the US FDA on a supplemental NDA for an additional dosing regimen for bivalirudin in treatment of acute coronary syndromes in the ED.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top